Daily ReportOct 30, 2026
Sepsis, October 30 edition
We read 34 papers and selected 3.
Summary
Today’s most impactful sepsis research identified two metabolically driven disease mechanisms and one pathogen-mediated thromboinflammatory mechanism. Experimental studies linked lactate-induced adipose tissue browning and microbiota-dependent citrulline metabolism to systemic inflammation and organ injury, while another study demonstrated that Staphylococcus aureus coagulases amplify fibrinogen-dependent NETosis and early immunothrombosis.
Research Themes
- Sepsis immunometabolism and adipose tissue remodeling
- Gut microbiota–immune axis and intestinal barrier repair
- Pathogen-driven thromboinflammation and NETosis
Selected Articles
1. Lactate Drives Pathological Browning of White Adipose Tissue to Aggravate Sepsis-Associated Metabolic Disorders in a GPR81-Dependent Manner.
This study demonstrates that lactate is an upstream driver of sepsis-associated metabolic dysfunction rather than only a marker of disease severity. Clinical observations, UCP1-deficient mice, GPR81 knockout models, adipose-specific knockdown, and primary adipocyte experiments converged on a lactate–GPR81–CTRP6/p38–UCP1 pathway that promotes pathological white adipose tissue browning, hypermetabolism, muscle wasting, and insulin resistance.
Impact: The work expands the biological interpretation of hyperlactatemia from a prognostic marker to a potentially causal metabolic signal. It identifies GPR81 and adipose tissue browning as experimentally testable therapeutic targets for persistent metabolic dysfunction that is not corrected by antimicrobial treatment alone.
Clinical Implications: Lactate-lowering or GPR81-directed interventions may eventually complement infection control and nutritional support in septic patients with persistent hypermetabolism and wasting. However, the findings do not yet justify clinical inhibition of lactate signaling because efficacy and safety in humans remain untested.
Key Findings
- Septic patients showed hyperlactatemia and white adipose tissue browning, with lactate levels correlating with fat and muscle loss.
- UCP1 deletion attenuated sepsis-induced hypermetabolism, muscle wasting, and insulin resistance, supporting a causal role for adipose tissue browning.
- Genetic and pharmacological experiments identified GPR81-mediated CTRP6/p38 signaling as a regulator of UCP1 upregulation and pathological browning.
Methodological Strengths
- Integrated clinical observations with gene-knockout mice, adipose-specific viral manipulation, pharmacological perturbation, and primary adipocyte experiments.
- Used mechanistic rescue and loss-of-function approaches to connect lactate signaling with UCP1-dependent metabolic phenotypes.
Limitations
- The experimental findings were primarily derived from preclinical models and do not establish therapeutic efficacy in humans.
- The clinical observations linking lactate to fat and muscle loss are associative and may be influenced by illness severity, nutrition, and treatment exposures.
Future Directions: Future studies should validate the lactate–GPR81 pathway in well-characterized longitudinal human cohorts and test whether selective modulation of adipose tissue browning improves recovery without impairing protective energy adaptation or immune function.
Lactate serves as a prognostic biomarker for sepsis, yet its adipose-centered signaling pathway driving persistent metabolic disorders remains unclear. We reveal that lactate accumulation triggers browning of white adipose tissue (WAT) via GPR81 to aggravate sepsis-induced hypermetabolism, muscle wasting, and insulin resistance. Septic patients exhibit hyperlactatemia and WAT browning, with lactate concentrations correlated with fat and muscle loss. Genetically deleting UCP1 substantially attenuates LPS-induced hypermetabolism, muscle wasting, and insulin resistance, confirming WAT browning as a major mediator of sepsis-associated metabolic disorders.
2. Staphylococcal coagulases amplify fibrinogen-dependent NETosis by S. aureus in human neutrophils and exacerbate early thromboinflammation in mice.
This study shows that staphylococcal coagulases shape early thromboinflammation through a mechanism distinct from generalized neutrophil activation. In human neutrophils, wild-type MRSA induced NET formation that was amplified by fibrinogen and was absent with coagulase-deficient bacteria; in mice, coagulases promoted early inflammatory responses, neutrophil recruitment, and VWF-rich hepatic thrombi.
Impact: The study provides a direct mechanistic link between a pathogen virulence factor, fibrinogen, NETosis, and organ immunothrombosis. It refines the understanding of Staphylococcus aureus sepsis by showing that coagulation manipulation can alter innate immune effector responses without necessarily causing sustained systemic coagulation activation.
Clinical Implications: The findings support investigation of coagulase–fibrinogen interactions and NETosis as potential therapeutic targets in severe S. aureus bloodstream infection. They also caution against assuming that absence of sustained coagulation activation excludes clinically relevant pathogen-driven immunothrombosis.
Key Findings
- Wild-type MRSA, but not coagulase-deficient MRSA, induced fibrinogen-enhanced NET formation in human neutrophils.
- NET formation was independent of canonical CD11b activation and degranulation pathways.
- In septic mice, coagulases increased early acute-phase reactants, neutrophil recruitment, and VWF-rich hepatic thrombi.
- Coagulases primarily influenced early inflammatory and endothelial responses rather than sustained systemic coagulation activation.
Methodological Strengths
- Used matched wild-type and coagulase-deficient MRSA strains in human neutrophil assays and an in vivo mouse infection model.
- Combined flow cytometry, NET assays with defined coagulation substrates, systemic inflammatory measurements, and hepatic immunothrombosis analysis.
Limitations
- The mouse model used intravenous infection and may not fully reproduce the source, timing, and heterogeneity of human S. aureus sepsis.
- The study establishes mechanistic associations but does not demonstrate that pharmacological inhibition of coagulases or NETosis improves survival or organ function.
Future Directions: Future research should determine whether coagulase-directed antibodies, fibrinogen modulation, or selective NETosis inhibition can reduce organ immunothrombosis while preserving antimicrobial host defense, and should validate these mechanisms in clinically representative infection models.
Bloodstream Staphylococcus aureus infections activate the host's thromboinflammatory response. Staphylocoagulases (Coa and vWbp) are virulence factors that manipulate the host coagulation system that may influence downstream neutrophil responses. We therefore investigated how coagulase-host interactions influence neutrophil activation, neutrophil extracellular trap (NET) formation, and systemic thromboinflammation. Human neutrophils were stimulated with methicillin-resistant S. aureus (MRSA) USA300 wild-type (WT) or coagulase-deficient (ΔcoaΔvwb) strains, and functional activation was analyzed by flow cytometry. NET formation was evaluated from bacteria that had been pre-incubated with fibrinogen, prothrombin, or both.
3. Microbiota-dependent citrulline metabolism alleviates sepsis by activating the aryl hydrocarbon receptor/IL-22 pathway to restore intestinal homeostasis.
The study identifies microbiota-dependent citrulline metabolism as a modifiable gut–immune pathway in sepsis. In vitro co-culture and cecal ligation and puncture models showed that citrulline-derived short-chain fatty acids and indole metabolites activate the AhR/IL-22/STAT3 axis, restore intestinal barrier and immune balance, and reduce intestinal, pulmonary, and hepatic inflammatory injury.
Impact: This paper moves beyond generic probiotic or nutritional concepts by linking a defined nutrient, microbial metabolites, and a specific host signaling pathway to intestinal repair during sepsis. It provides a mechanistic basis for precision nutritional or microbiota-targeted interventions, while clearly indicating that translation to patients remains necessary.
Clinical Implications: Citrulline supplementation or microbiota-directed nutritional therapy may become an adjunctive strategy to preserve intestinal barrier function and reduce systemic inflammation in sepsis. Clinical trials must first establish dose, timing, microbiome dependence, safety, and effects on patient-centered outcomes.
Key Findings
- Citrulline fermentation increased short-chain fatty acids and indole derivatives in an in vitro microbiota co-culture system.
- Citrulline activated AhR signaling, increased IL-22 secretion and STAT3 phosphorylation, and improved the Treg/Th17 balance.
- In cecal ligation and puncture mice, citrulline reduced intestinal injury and neutrophil infiltration, improved goblet cell and tight-junction features, and attenuated lung and liver inflammation.
- Antibiotic treatment or AhR inhibition diminished the protective effects, supporting microbiota and AhR dependence.
Methodological Strengths
- Combined microbiota co-culture, a clinically relevant polymicrobial sepsis model, pathway inhibition, immune profiling, and RNA sequencing.
- Used antibiotic depletion and AhR/STAT3 inhibition to test whether the observed effects depended on microbial metabolism and defined host signaling.
Limitations
- The evidence is based mainly on in vitro systems and mouse cecal ligation and puncture models, whose microbiota and disease kinetics may differ from humans.
- The specific bacterial taxa responsible for beneficial citrulline metabolism and the optimal clinical dose and timing were not established.
Future Directions: Future work should identify the responsible microbial taxa and metabolites, assess whether baseline microbiome composition predicts response, and conduct carefully designed clinical trials of citrulline or microbiota-targeted interventions in biologically defined sepsis subgroups.
This study investigated whether citrulline ameliorates sepsis-associated immune inflammation and intestinal barrier injury by modulating gut microbiota metabolites. Using an in vitro co-culture system and a cecal ligation and puncture mouse model, we found that citrulline fermentation products significantly increased the production of short-chain fatty acids and indole derivatives. These metabolic changes activated the aryl hydrocarbon receptor (AhR) pathway, upregulated interleukin-22 (IL-22) secretion, STAT3 phosphorylation, and restored the Treg/Th17 cell balance. Consequently, intestinal barrier function was improved, as evidenced by enhanced expression and membrane localization of tight junction proteins, and increased antimicrobial peptide production.